
US-based Lohocla leads in R&D, innovating chronic pain medication solutions.
Lohocla Research Corporation is dedicated to the research and development of innovative medications for chronic pain and addiction. Based in Aurora, United States, Lohocla focuses on addressing the debilitating effects of these conditions by exploring neural system maladaptations. The company aims to restore the full spectrum of life’s enjoyments to individuals suffering from severe chronic pain and addiction, which often isolate them from social connections.
Lohocla has made significant strides in understanding the neural mechanisms underlying chronic pain and addiction. By leveraging advanced bioscience research, the company has developed potential therapeutic solutions that target these complex conditions. Lohocla's commitment to innovation and its impact on improving quality of life for patients underscore its role as a leader in the field of chronic pain and addiction treatment.

NeuraLace Medical

Doloromics
doloromics.com

Solace Pharmaceuticals

Akelos
akelosinc.com

Latigo Biotherapeutics
latigobio.com

NeuroTherapeutics Pharma

Aiko Biotechnology

Concentric Analgesics

NeurOp

Aponia Laboratories

Embera Neurotherapeutics
emberaneuro.com

Amygdala Neurosciences
amygns.com

Neurana Pharmaceuticals
neuranapharma.com

EicOsis
eicosis.com

Neurocarrus
neurocarrus.com
Companies similar to Lohocla Research include NeuraLace Medical, Doloromics, Solace Pharmaceuticals and Akelos.
Lohocla Research was founded in 1983.
Lohocla Research's headquarters is located in Aurora, CO, US.
Lohocla Research's most recent funding round was for $3.3M (USD) in March 2020.
As of Mar 2, 2020, Lohocla Research has raised a total of $9.8M (USD).
Lohocla Research has 8 employees as of Feb 4, 2024.